

MEMORANDUM

Date: 20 SEPTEMBER 2021
Sponsor: Blade Therapeutics, Inc.
Protocol: A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate
Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered
Orally in Subjects with Idiopathic Pulmonary Fibrosis
(Protocol B-2660-203)

Subject: Cancellation of Clinical Study B-2660-203 Due to Concerns with COVID-19

TO WHOM IT MAY CONCERN:

Clinical Study B-2660-203, entitled “A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis,” was submitted to authorities but was cancelled and never initiated due to concerns with the COVID-19 pandemic at the time of study initiation.

Sincerely,



Daven Mody, PharmD, MBA
Vice President, Regulatory Affairs and Quality
Blade Therapeutics, Inc.